Loading...
XSHE
002262
Market cap2.92bUSD
Jul 10, Last price  
19.94CNY
1D
2.10%
1Q
-12.00%
Jan 2017
52.65%
IPO
860.91%
Name

Jiangsu Nhwa Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002262 chart
P/E
19.16
P/S
3.46
EPS
1.04
Div Yield, %
1.84%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
11.72%
Revenues
5.85b
+2.67%
695,840,266804,825,180952,499,5601,110,938,9541,300,610,8171,587,499,7321,982,496,3932,236,077,0142,501,358,7492,766,567,6223,017,785,7593,393,676,9553,858,168,5904,149,312,4253,361,303,4713,935,664,2184,298,513,0615,041,504,4665,697,633,0435,849,711,000
Net income
1.06b
-7.54%
16,983,07226,655,71840,699,44454,673,00976,435,323105,647,054139,697,898176,253,606223,271,127258,347,056309,743,047394,634,283524,807,855663,308,788728,821,693797,777,334900,709,3321,036,918,0601,143,564,4321,057,334,000
CFO
1.12b
+22.77%
30,989,08248,550,88646,500,88461,271,78761,791,82381,076,208154,164,158194,332,052160,236,857204,235,003277,141,381452,348,798404,524,742305,972,8551,248,348,649701,117,596861,023,1491,008,300,046916,126,5031,124,757,753
Dividend
May 14, 20250.36 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Jiangsu Nhwa Pharmaceutical Co., LTD operates as a global pharmaceutical entity, focusing on the research, production, and sale of treatments for the central nervous system, along with cardiovascular and cerebrovascular ailments. Its comprehensive product line includes therapeutics for anesthesia, psychiatry, and neurological disorders. Additionally, the company is a supplier of Active Pharmaceutical Ingredients (APIs), specifically for central nervous system, anesthetic, and sedative applications, among others. The firm was established in 1978 and is based in Xuzhou, China.
URL
https://www.nhwa-group.com/
IPO date
Jul 23, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT